Market Overview

Mid Cap Biotechs May Outperform In 2010


Analysts at Cowen and Company say that their expectation for a strong earnings season is underlined by positive fluctuations in foreign currency, favorable seasonal demand trends and a continued open pricing environment.

Cowen and Company expects emerging product companies to offer profit-making opportunities to investors in 2010. Acorda Therapeutics Inc (NASDAQ: ACOR), Affymax Inc (NASDAQ: AFFY), Alexion Pharmaceuticals Inc (NASDAQ: ALXN), Amgen Inc (NASDAQ: AMGN), Auxilium Pharmaceuticals Inc (NASDAQ: AUXL), Biogen Idec Inc (NASDAQ: BIIB) and Gilead Sciences Inc ((NASDAQ: GILD) are among the favorites for this year.

Cowen and Company believes that demand trends of the biotech sector remain solid, while the US dollar has lost roughly 3% of its value over the past three months. This may prove beneficial for Alexion Pharmaceuticals (NASDAQ: ALXN), GILD and BioMarin Pharmaceuticals (NASDAQ: BMRN). Cowen and Company believes that mid cap biotechs may outperform the large and small caps in 2010.

Check more Analyst Ratings


Related Articles (ACOR + AFFY)

View Comments and Join the Discussion!

Posted-In: biotech sector Cowen and Company Mid Cap Biotechs US DollarLong Ideas Analyst Ratings Trading Ideas

Latest Ratings

CPBWells FargoMaintains54.0
BZUNB of A SecuritiesMaintains36.0
ADSKWells FargoMaintains250.0
AATWells FargoMaintains33.0
ZUOCanaccord GenuityMaintains19.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at